A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

Purpose

This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Condition

  • Healthy

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • BMI of 16-32 kg/m2; and a total body weight >50 kg (110 lb). - Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Participants should be able to understand and sign informed consent

Exclusion Criteria

  • Evidence or history of clinically significant any medical condition - History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb. - Evidence of active, latent, or inadequately treated infection with Mycobacterium TB - History of allergic or anaphylactic reaction with any biologic agents.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
tilrekimig and rHuPH20 		a single dose of co-mixed tilrekimig and rHuPH20
  • Drug: tilrekimig and rHuPH20
    subcutaneous injection

Recruiting Locations

New Haven Pfizer Clinical Research Unit (NH PCRU)
New Haven, Connecticut 06511

More Details

Status
Recruiting
Sponsor
Pfizer

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com